Assertio Therapeutics Stock Today
| ASRT Stock | USD 1.01 0.07 7.45% |
Performance0 of 100
| Odds Of DistressOver 67
|
Assertio Therapeutics is selling for under 1.01 as of the 25th of November 2024; that is 7.45 percent increase since the beginning of the trading day. The stock's last reported lowest price was 0.94. Assertio Therapeutics has more than 67 % chance of experiencing financial distress in the next few years of operation. It also generated negative returns for investors over the last 90 days. Equity ratings for Assertio Therapeutics are calculated daily based on our scoring framework. The performance scores are derived for the period starting the 26th of October 2024 and ending today, the 25th of November 2024. Click here to learn more.
Business Domain Pharmaceuticals, Biotechnology & Life Sciences | IPO Date 5th of November 1997 | Category Healthcare | Classification Health Care |
Assertio Holdings, Inc., a specialty pharmaceutical company, provides medicines in the areas of neurology, hospital, and pain and inflammation. Assertio Holdings, Inc. was incorporated in 1995 and is headquartered in Lake Forest, Illinois. Assertio Holdings operates under Drug ManufacturersSpecialty Generic classification in the United States and is traded on NASDAQ Exchange. The company has 95.34 M outstanding shares of which 6.09 M shares are presently shorted by private and institutional investors with about 14.28 trading days to cover. More on Assertio Therapeutics
Moving together with Assertio Stock
Moving against Assertio Stock
Follow Valuation Profit Patterns Odds of Bankruptcy
Check how we calculate scores
Assertio Stock Highlights
| CEO Director | Brendan OGrady | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Business Concentration | Pharmaceuticals, Pharmaceuticals, Biotechnology & Life Sciences, Health Care, NASDAQ Composite, NASDAQ Health Care, Health Care, Pharmaceuticals, Drug Manufacturers—Specialty & Generic, Healthcare (View all Sectors) | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Average Analyst Recommendation | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Financial Strength
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Debt LevelsAssertio Therapeutics can leverage the use of borrowed funds to amplify returns from an investment. In general, analyzing the relationship between debt to total assets helps investors to understand Assertio Therapeutics' financial leverage. It provides some insight into what part of Assertio Therapeutics' total assets is financed by creditors.
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Assertio Therapeutics (ASRT) is traded on NASDAQ Exchange in USA. It is located in 100 South Saunders Road, Lake Forest, IL, United States, 60045 and employs 53 people. Assertio Therapeutics is listed under Pharmaceuticals category by Fama And French industry classification. The company currently falls under 'Micro-Cap' category with a current market capitalization of 81.8 M. Assertio Therapeutics conducts business under Pharmaceuticals sector and is part of Health Care industry. The entity has 95.34 M outstanding shares of which 6.09 M shares are presently shorted by private and institutional investors with about 14.28 trading days to cover.
Assertio Therapeutics currently holds about 52.26 M in cash with 49.6 M of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 1.09, which can makes it an attractive takeover target, given it will continue generating positive cash flow.
Check Assertio Therapeutics Probability Of Bankruptcy
Ownership AllocationAssertio Therapeutics holds a total of 95.34 Million outstanding shares. 30% of Assertio Therapeutics outstanding shares are owned by other corporate entities. Institutional investors are typically referred to investors that purchase positions in a given stock to benefit from reduced commissions. Consequently, institutional investors are subject to different rules and regulations than regular investors. Please look out for any change in current institutional holding as this could mean something significant has changed at the company or is about to change. Please note that no matter how many assets the company secures, if the real value of the firm is less than the current market value, you may not be able to make money on it.
Check Assertio Ownership Details
Assertio Stock Institutional Holders
| Instituion | Recorded On | Shares | |
| Two Sigma Investments Llc | 2024-09-30 | 876 K | |
| Amvescap Plc. | 2024-06-30 | 564.1 K | |
| Bridgeway Capital Management, Llc | 2024-09-30 | 498.6 K | |
| Susquehanna International Group, Llp | 2024-06-30 | 490.3 K | |
| Empowered Funds, Llc | 2024-06-30 | 409.9 K | |
| Jane Street Group Llc | 2024-06-30 | 406.6 K | |
| Perritt Capital Management Inc. | 2024-09-30 | 390.1 K | |
| Bank Of New York Mellon Corp | 2024-06-30 | 351.7 K | |
| State Street Corp | 2024-06-30 | 339.3 K | |
| Nantahala Capital Management, Llc | 2024-09-30 | 8.9 M | |
| Vanguard Group Inc | 2024-09-30 | 4.5 M |
Assertio Therapeutics Historical Income Statement
Assertio Stock Against Markets
Assertio Therapeutics Corporate Management
| Jack Hoblitzell | VP Operations | Profile | |
| MD MBA | Senior Medical | Profile | |
| Ajay Patel | VP Officer | Profile | |
| Sam Schlessinger | Senior Counsel | Profile | |
| Molly Dir | Senior Administration | Profile | |
| Bill Iskos | Senior Operations | Profile |
Already Invested in Assertio Therapeutics?
The danger of trading Assertio Therapeutics is mainly related to its market volatility and Company specific events. As an investor, you must understand the concept of risk-adjusted return before you start trading. The most common way to measure the risk of Assertio Therapeutics is by using the Sharpe ratio. The ratio expresses how much excess return you acquire for the extra volatility you endure for holding a more risker asset than Assertio Therapeutics. The Sharpe ratio is calculated by using standard deviation and excess return to determine reward per unit of risk. To understand how volatile Assertio Therapeutics is, you must compare it to a benchmark. Traditionally, the risk-free rate of return is the rate of return on the shortest-dated U.S. Treasury, such as a 3-year bond.
Additional Tools for Assertio Stock Analysis
When running Assertio Therapeutics' price analysis, check to measure Assertio Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Assertio Therapeutics is operating at the current time. Most of Assertio Therapeutics' value examination focuses on studying past and present price action to predict the probability of Assertio Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Assertio Therapeutics' price. Additionally, you may evaluate how the addition of Assertio Therapeutics to your portfolios can decrease your overall portfolio volatility.